U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Ceftriaxone - Injection products
  1. Development Resources

Ceftriaxone - Injection products

Exceptions or additions to the recognized standards

 

Minimum Inhibitory Concentrations
(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Anaerobes

≤1

2

≥4

-

-

-

S = Susceptible; I = Intermediate; R = Resistant

For Haemophilus influenzae and parainfluenzae, susceptibility interpretive criteria recognized in CLSI M100 are based on a dose of 2 grams IV every 24 hours in patients with normal renal function.

For the bacteria listed below, susceptibility test interpretive criteria are not recognized at this time:

Acinetobacter spp

Other Non-Enterobacterales

Back to Top